Pharmaceutical research and development for medicines including cannabinoids and/or cannabidiol (CBD), with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, for the treatment of refractory epilepsy, epilepsy, autism and anxiety; scientific and medical research in the field of cannabinoids and/or cannabidiol (CBD) contained medicines, with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, for the treatment of refractory epilepsy, epilepsy, autism and anxiety

'-9':15,57 '0.3':23,65 'and/or':9,49 'anxieti':39,81 'autism':37,79 'basi':29,71 'cannabidiol':10,50 'cannabinoid':8,48 'cbd':11,51 'concentr':18,60 'contain':52 'delta':14,56 'develop':4 'dri':27,69 'epilepsi':35,36,77,78 'field':46 'includ':7 'medic':42 'medicin':6,53 'percent':24,66 'pharmaceut':1 'refractori':34,76 'research':2,43 'scientif':40 'tetrahydrocannabinol':16,58 'thc':17,59 'treatment':32,74 'weight':28,70

Medicines for the treatment of refractory epilepsy, epilepsy, autism, anxiety including cannabinoids and/or cannabidiol (CBD), with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis

'-9':19 '0.3':27 'and/or':13 'anxieti':10 'autism':9 'basi':33 'cannabidiol':14 'cannabinoid':12 'cbd':15 'concentr':22 'delta':18 'dri':31 'epilepsi':7,8 'includ':11 'medicin':1 'percent':28 'refractori':6 'tetrahydrocannabinol':20 'thc':21 'treatment':4 'weight':32

ENTOURAGE PHYTOLAB

Owner

Goods & Services